167 related articles for article (PubMed ID: 36203562)
1. Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer.
Song J; Wei R; Huo S; Liu C; Liu X
Front Immunol; 2022; 13():960570. PubMed ID: 36203562
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis of the prognosis and biological significance of VCAN in gastric cancer.
Huang XY; Liu JJ; Liu X; Wang YH; Xiang W
Immun Inflamm Dis; 2021 Jun; 9(2):547-559. PubMed ID: 33631054
[TBL] [Abstract][Full Text] [Related]
3. Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer.
Song J; Wei R; Huo S; Gao J; Liu X
Front Immunol; 2022; 13():920512. PubMed ID: 35769483
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive MFAP2
Wei R; Song J; Liu X; Huo S; Liu C; Liu X
Cell Oncol (Dordr); 2024 Feb; 47(1):55-68. PubMed ID: 37540308
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed versican promoted cell multiplication, migration and invasion in gastric cancer.
Zhai L; Chen W; Cui B; Yu B; Wang Y; Liu H
Tissue Cell; 2021 Dec; 73():101611. PubMed ID: 34358918
[TBL] [Abstract][Full Text] [Related]
6. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.
Zhang Q; Wu J; Chen X; Zhao M; Zhang D; Gao F
Biomed Res Int; 2021; 2021():6949864. PubMed ID: 33604385
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
9. Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.
Mitsui Y; Shiina H; Kato T; Maekawa S; Hashimoto Y; Shiina M; Imai-Sumida M; Kulkarni P; Dasgupta P; Wong RK; Hiraki M; Arichi N; Fukuhara S; Yamamura S; Majid S; Saini S; Deng G; Dahiya R; Nakajima K; Tanaka Y
Mol Cancer Res; 2017 Jul; 15(7):884-895. PubMed ID: 28242813
[TBL] [Abstract][Full Text] [Related]
10. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
11. Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer.
Sun Y; Chen Y; Zhuang W; Fang S; Chen Q; Lian M; Lv C; Weng J; Wei R; Lin Y; Cai L; Wang Q
J Cell Mol Med; 2023 Nov; 27(22):3578-3590. PubMed ID: 37605453
[TBL] [Abstract][Full Text] [Related]
12. The expression of versican and its role in pancreatic neuroendocrine tumors.
Gao H; Cheng Y; Chen Y; Luo F; Shao Y; Sun Z; Bai C
Pancreatology; 2020 Jan; 20(1):142-147. PubMed ID: 31771905
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.
Chen Y; Sun Z; Wan L; Chen H; Xi T; Jiang Y
Front Immunol; 2022; 13():890922. PubMed ID: 35572498
[TBL] [Abstract][Full Text] [Related]
14. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.
Hope C; Emmerich PB; Papadas A; Pagenkopf A; Matkowskyj KA; Van De Hey DR; Payne SN; Clipson L; Callander NS; Hematti P; Miyamoto S; Johnson MG; Deming DA; Asimakopoulos F
J Immunol; 2017 Sep; 199(5):1933-1941. PubMed ID: 28754680
[TBL] [Abstract][Full Text] [Related]
15.
Cheng Y; Sun H; Wu L; Wu F; Tang W; Wang X; Lv C
Onco Targets Ther; 2020; 13():8665-8675. PubMed ID: 32922041
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer.
Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D
Front Immunol; 2020; 11():609337. PubMed ID: 33569057
[TBL] [Abstract][Full Text] [Related]
17. Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate.
Hirani P; McDermott J; Rajeeve V; Cutillas PR; Jones JL; Pennington DJ; Wight TN; Santamaria S; Alonge KM; Pearce OMT
Cancer Res Commun; 2024 Apr; 4(4):970-985. PubMed ID: 38517140
[TBL] [Abstract][Full Text] [Related]
18. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.
Gupta N; Kumar R; Seth T; Garg B; Sharma A
RNA Biol; 2020 Jan; 17(1):98-111. PubMed ID: 31532704
[TBL] [Abstract][Full Text] [Related]
19. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
20. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
